phone iconPhone: (401) 822-4673
phone iconFax: (401) 822-4676
Receive our Health e-Newsletter

News for Healthier Living

Rethinking Triple-Negative Breast Cancer Treatment Through EGFR Co-Targeting and Nanotechnology

Triple-negative breast cancer (TNBC) remains one of the most challenging forms of breast cancer to treat because it lacks the estrogen, progesterone and HER2 receptors that enable targeted treatment in other breast cancer subtypes. A review published in Genes & Diseases examines how targeting the epidermal growth factor receptor (EGFR) alongside other molecular targets, supported by nanocarrier-based delivery, could offer new possibilities for more precise TNBC treatment.

September 25, 2026


September 25 2026

September 24 2026

September 23 2026

September 22 2026

September 21 2026

September 18 2026

September 17 2026

September 16 2026

September 15 2026

September 14 2026

September 11 2026

Angell Street Psychiatry
Copyright 2026 HealthBanks, Inc. All rights reserved.
Terms of Use | Privacy Policy